Using economic analyses for local priority setting: The population cost-impact approach

Applied Health Economics and Health Policy

Volumn 5, Issue 1, 2006, Pages 45-54

  Heller, Richard F ^a   Gemmell, Islay ^a   Wilson, Edward C F ^b   Fordham, Richard ^b   Smith, Richard D ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEALTH ECONOMICS; HEART INFARCTION; HUMAN; POPULATION; QUALITY ADJUSTED LIFE YEAR; QUESTIONNAIRE; SMOKING CESSATION; UNITED KINGDOM;

ADRENERGIC BETA-ANTAGONISTS; AGED; COSTS AND COST ANALYSIS; EVALUATION STUDIES; FEMALE; GREAT BRITAIN; HEALTH PRIORITIES; HOSPITALS, PUBLIC; HUMANS; MALE; MIDDLE AGED; PUBLIC HEALTH; QUESTIONNAIRES; SMOKING CESSATION;

EID: 33745242297     PISSN: 11755652     EISSN: 11755652     Source Type: Journal    
DOI: 10.2165/00148365-200605010-00006     Document Type: Article

References (47)

1. Wanless D. Securing good health for the whole population. London: HMSO, 2004
2. Coast J. Is economic evaluation in touch with society's health values? BMJ 2004; 329 (7476): 1233-6
3. Smith J, Mays N. Primary care trusts: do they have a future? BMJ 2005; 331 (7526): 1156-7
4. Smith J, Dixon J, Mays N, et al. Practice based commissioning: applying the research evidence. BMJ 2005; 331: 1397-9
5. Oliver A. Putting the quality into quality-adjusted life years. J Public Health Med 2003; 25 (1): 8-12
6. Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ 2004; 329 (7459): 224-7
7. Gafni A, Birch S. NICE methodological guidelines and decision making in the National Health Service in England and Wales. Pharmacoeconomics 2003; 21 (3): 149-57
8. Maynard A, Bloor K, Freemantle N. Challenges for the national institute for clinical excellence. BMJ 2004; 329 (7459): 227-9
9. Briggs A, Gray A. Using cost effectiveness information. BMJ 2000; 320 (7229): 246
10. Wilson E, Rees J, Fordham R. Developing a prioritisation framework in an English Primary Care Trust. Cost Eff Resour Alloc 2006; 4 (1): 3
11. Heller RF, Dobson AJ. Disease impact number and population impact number: a population perspective to measures of risk and benefit. BMJ 2000; 321: 950-2
12. Heller RF, Dobson AJ, Attia J, et al. Impact numbers: measures of risk factor impact on the whole population from case control and cohort studies. J Epidemiol Community Health 2002; 56: 606-10
13. Attia J, Page JH, Heller RF, et al. Impact numbers in health policy decisions. J Epidemiol Community Health 2002; 56 (8): 600-5
14. Heller RF, Edwards R, McElduff P. Implementing guidelines in primary care: can population impact measures help? BMC Public Health 2003; 3: 7
15. Heller RF, Buchan I, Edwards R, et al. Communicating risks at the population level: application of population impact numbers. BMJ 2003; 327 (7424): 1162-5
16. Cook R, Sackett D. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995; 310: 452-4
17. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001; 10 (8): 779-87
18. Sendi PP, Briggs AH. Affordability and cost-effectiveness: decision-making on the cost-effectiveness plane. Health Econ 2001; 10 (7): 675-80
19. Middleton E, Baker D. Comparison of social distribution of immunisation with measles, mumps, and rubella vaccine, England, 1991-2001. BMJ 2003; 326 (7394): 854
20. Mitton C, Donaldson C. Health care priority setting: principles, practice and challenges. Cost Eff Resour Alloc 2004; 2 (1): 3
21. Gemmell I, Heller RF, McElduff P, et al. Population impact of stricter adherence to recommendations for pharmacological and lifestyle interventions over one year in patients with coronary heart disease. J Epidemiol Community Health 2005; 59 (12): 1041-6
22. Netten A, Curtis L. Unit costs of Health and Social Care 2003. Canterbury: Personal Social Services Research Unit, University of Kent, 2003
23. Wu LA, Kottke TE. Number needed to treat: caveat emptor. J Clin Epidemiol 2001; 54 (2): 111-6
24. Kassai B, Gueyffier F, Boissel JP, et al. Absolute benefit, number needed to treat and gain in life expectancy: which efficacy indices for measuring the treatment benefit? J Clin Epidemiol 2003; 56 (10): 977-82
25. Kristiansen IS, Gyrd-Hansen D. Cost-effectiveness analysis based on the number-needed-to-treat: common sense or nonsense? Health Econ 2004; 13 (1): 9-19
26. Mauskopf J, Rutten F, Schonfeld W. Cost-effectiveness league tables: valuable guidance for decision makers? Pharmacoeconomics 2003; 21 (14): 991-1000
27. Smith R, Richardson J. Can we estimate the 'social' value of a QALY? Four core issues to resolve. Health Policy 2005 Sep 28; 74 (1): 77-84
28. Primatesta P. Prevalence of cardiovascular disease. Health Survey for England 1998. London: The Stationery Office, 1999
29. Capewell S, Livingston BM, MacIntyre K, et al. Trends in case-fatality in 117 718 patients admitted with acute myocardial infarction in Scotland. Eur Heart J 2000; 21 (22): 1833-40
30. Freemantle N, Cleland J, Young P, et al. beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 318 (7200): 1730-7
31. Critchley JA, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease (Cochrane Review). The Cochrane Library. 2nd ed. Chichester: John Wiley & Sons, 2004
32. Sarasin FP, Maschiangelo ML, Schaller MD, et al. Successful implementation of guidelines for encouraging the use of beta blockers in patients after acute myocardial infarction. Am J Med 1999; 106 (5): 499-505
33. Dudley NJ, Bowling A, Bond M, et al. Age- and sex-related bias in the management of heart disease in a district general hospital. Age Ageing 2002; 31 (1): 37-42
34. Brotons C, Permanyer G, Pacheco V, et al. Prophylactic treatment after myocardial infarction in primary care: how far can we go? Fam Pract 2003; 20 (1): 32-5
35. Brotons C, Calvo F, Cascant P, et al. Is prophylactic treatment after myocardial infarction evidence-based? [published erratum appears in Fam Pract 1999 Feb; 16 (1): 94]. Fam Pract 1998 Oct; 15 (5): 457-61
36. Jolly K, Bradley F, Sharp S, et al. Randomised controlled trial of follow up care in general practice of patients with myocardial infarction and angina: final results of the Southampton heart integrated care project (SHIP). BMJ 1999; 318 (7185): 706-11
37. Campbell NC, Thain J, Deans HG, et al. Secondary prevention in coronary heart disease: baseline survey of provision in general practice. BMJ 1998; 316 (7142): 1430-4
38. Kotseva K, Wood D, De Backer G, et al. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22 (7): 554-72
39. Flanagan DEH, Cox P, Paine D, et al. Secondary prevention of coronary heart disease in primary care: a healthy heart initiative. QJM 1999; 92 (5): 245-50
40. Feder G, Griffiths C, Eldridge S, et al. Effect of postal prompts to patients and general practitioners on the quality of primary care after a coronary event (POST): randomised controlled trial. BMJ 1999; 318 (7197): 1522-6
41. Fox KF, Wood DA, Wright M, et al. Evaluation of a cardiac prevention and rehabilitation programme for all patients at first presentation with coronary artery disease. J Cardiovasc Risk 2002; 9 (6): 355-9
42. Hippisley-Cox J, Pringle M, Crown N, et al. Sex inequalities in ischaemic heart disease in general practice: cross sectional survey. BMJ 2001; 322 (7290): 832
43. Carroll K, Majeed A, Firth C, et al. Prevalence and management of coronary heart disease in primary care: population-based cross-sectional study using a disease register. J Public Health Med 2003; 25 (1): 29-35
44. National Primary Care Research and Development Centre. Quality and Incentives in Practice (QuIP) database, 2005 [online]. Available from URL: http://www.npcrdc.man.ac.uk/ResearchDetail.cfm?ID=118&ExtSearch=Quip [Accessed 2006 Mar]
45. Simpson E, Beck C, Richard H, et al. Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence. Am Heart J 2003; 145 (3): 438-44
46. Eagle KA, Kline-Rogers E, Goodman SG, et al. Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. Am J Med 2004; 117 (2): 73-81
47. Corrigan M, Cupples ME, Stevenson M. Quitting and restarting smoking: cohort study of patients with angina in primary care. BMJ 2002; 324 (7344): 1016-7